A Phase 3, Randomized, Controlled, Double-Arm, Open- Label, Multi-center Study of VB-111 Combined with Bevacizumab vs. Bevacizumab Monotherapy in Patients with Recurrent Glioblastoma
A study for patients with recurrent Glioblastoma using study drug VB-111
Sponsor: Vascular Biogenics
Enrolling: Male and Female Patients
IRB Number: AAAQ1153
U.S. Govt. ID: NCT02511405
Contact: Teri Kreisl: 212-342-0571 / tnk2109@cumc.columbia.edu
Additional Study Information: This is a research study to test the effects of VB-111 combined with Bevacizumab versus Bevacizumab alone on glioblastoma . This study will enroll 252 subjects age 18 years and older who have recurrent glioblastoma. All subjects will be randomly assigned in a 1:1 ratio to receive either VB-111 combined with Bevacizumab or Bevacizumab alone. Survival, tumor response, and tumor growth rate will be used to determine the effectiveness of each treatment. As the best treatment for patients with recurrent glioblastoma is not known, this study may help identify an effective treatment with limited negative side effects.
This study is closed
Teri Kreisl, MD
Do You Qualify?
Have you been diagnosed with Glioblastoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Teri Kreisl